I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 10, 2002

Signature: (Thomas J. Wrona, Ph.D.)

OCT 2 1 2002

Docket No.: 29264/38278

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:

Minas T. Coroneo

Application No.: 10/084,604

Group Art Unit: 1614

Filed: February 27, 2002

Examiner: Not Yet Assigned

For:

METHODS FOR PREVENTING PRESSURE

INDUCED APOPTOTIC NEURAL CELL

DEATH

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

The publications in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application no. 09/649,643 filed August 29, 2000, and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an

Application No.: 10/084,604 Docket No.: 29264/38278

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: October 10, 2002

Respectfully submitted,

Thomas J. Wrong, Ph.D.

Registration No.: 44,410

MARSHALL, GERSTEIN & BORUN

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorneys for Applicant